Annals of Pharmacy Practice and Pharmacotherapy
ISSN: 3062-4436
2023, Volume 3, Issue 2, Page No: 51-62

Available online at: www.galaxypub.co/page/journals

Galaxy Publication

Counting Pharmacist Interventions Cannot Establish Pharmaceutical-Care Value Without Evidence Linking Delivered Care to Patient Benefit

Elena Petrova[1]*, Ravi Patel[2], Ingrid Larsen[3], Samuel Boateng[4]

[1]Department of Pharmaceutical Care and Outcomes Research, Faculty of Pharmacy, Sofia University, Sofia, Bulgaria.
[2]Department of Pharmacy Practice and Health Services Research, Faculty of Pharmacy, Indian Institute of Management Bangalore, Bangalore, India.
[3]Department of Clinical Pharmacy and Patient Outcomes, Faculty of Health Sciences, University of Oslo, Oslo, Norway.
[4]Department of Pharmacy Administration and Health Policy, School of Pharmacy, University of Cape Coast, Cape Coast, Ghana.

***E-mail** ✉ elena.petrova@uni-sofia.bg
Received: 01 June 2023; **Revised:** 04 September 2023; **Accepted:** 07 September 2023

ABSTRACT

Pharmacist services are commonly evaluated using counts of interventions, recommendations, accepted recommendations, medication-related problems addressed, or other process measures. These indicators are important for describing workload, service reach, and implementation, but they occupy different positions in the causal sequence between pharmacist activity and patient benefit. A recommendation may never be accepted; an accepted recommendation may never be implemented; a medication modification may not persist; and a successfully implemented change may alter a medication-related intermediate outcome without improving an outcome that matters directly to the patient. Conversely, pharmacist interventions can generate patient benefit through mechanisms that do not require a medication change, including education, monitoring, adherence support, and communication. These possibilities make pharmaceutical-care value an attribution problem rather than a counting problem. This article develops an evidence-bounded causal interpretation of pharmacist-service evaluation by distinguishing service production, clinician uptake, actual medication modification, intermediate medication outcomes, and patient-important outcomes. Evidence from medication-review studies shows substantial heterogeneity across intervention components, implementation processes, endpoints, and observed effects. Studies that separately measure recommendation generation, acceptance, actioning, and implementation demonstrate that these stages cannot be treated as equivalent exposures. Medication-related outcomes such as drug-related problems, discrepancies, adherence, or medication burden provide stronger evidence of pathway activity than intervention counts, yet still require careful interpretation before patient benefit is attributed. Actual adverse drug events are also directly patient-important outcomes. Credible evaluation therefore depends on matching the strength of the causal claim to the level of outcome observed, the integrity of the implementation pathway, and the plausibility of competing explanations.

Keywords: Pharmacist interventions, Pharmaceutical care, Medication review, Treatment modification, Causal inference, Patient-important outcomes

How to Cite This Article: Petrova E, Patel R, Larsen I, Boateng S. Counting Pharmacist Interventions Cannot Establish Pharmaceutical-Care Value Without Evidence Linking Delivered Care to Patient Benefit. Ann Pharm Pract Pharmacother. 2023;3(2):51-62. https://doi.org/10.51847/8zPVVc0TOx

Introduction

Pharmacist-led medication review and pharmaceutical-care services are complex interventions rather than uniform technical acts. They can include medication reconciliation, medication-problem identification, recommendation generation, communication with prescribers, patient education, deprescribing support,

monitoring, follow-up, and repeated reassessment. A recent synthesis of randomized medication-review studies showed that intervention content, collaboration, patient involvement, follow-up, and implementation processes vary substantially across services and may relate differently to observed outcomes [1]. Consequently, a count such as “120 pharmacist interventions” has an unambiguous administrative meaning—it records service activity—but no equally unambiguous clinical meaning. The same count could represent minor documentation corrections, high-risk treatment changes, recommendations never communicated, recommendations declined after appropriate clinical review, or changes that were implemented and subsequently improved a clinically important outcome.

This distinction has become more important as the literature on pharmacist-led medication review has expanded. Community-pharmacy trials differ markedly in patient selection, review procedures, measured outcomes, instruments, and follow-up, producing substantial heterogeneity in what the term medication review represents [2]. At the same time, controlled evidence demonstrates that pharmacist interventions can improve meaningful outcomes in selected settings. Meta-analytic evidence has reported improvements in some clinical and health-service outcomes after community pharmacist medication review, cardiovascular umbrella reviews identify favorable effects across several risk-factor outcomes, and pharmacist interventions in residential aged care have prevented adverse drug events in a subset of studies [3-5]. These findings establish that pharmaceutical-care services can be effective. They do not make every recorded pharmacist activity an observable unit of patient benefit.

The unresolved methodological problem is therefore one of causal attribution. Service evaluation often moves rapidly from activity measures to statements about value, even though several empirically distinct events may intervene. Pharmacists first detect or formulate an issue. A recommendation may then be communicated. The clinician, patient, caregiver, or multidisciplinary team may accept, modify, defer, or reject it. Even after acceptance, implementation may be incomplete or delayed. If treatment changes, the change may or may not produce the expected pharmacological, behavioral, or safety consequence. Finally, an intermediate medication outcome may fail to translate into an improvement in symptoms, function, quality of life, serious harm, hospitalization, or another patient-important endpoint.

The central question is therefore: what causal evidence is required to move from counts of pharmacist activity to credible claims about treatment change and patient benefit**?** Addressing that question requires separating measures that are often combined under broad labels such as intervention rate, acceptance rate, medication optimization, clinical impact, or pharmaceutical-care outcome. The purpose is not to require every service evaluation to measure every possible downstream endpoint. It is to align the interpretation with what was actually observed. An activity count can credibly describe service production. Acceptance can describe uptake. Verified medication modification can demonstrate that pharmacotherapy changed. Intermediate outcomes can show that a medication-related process or state changed. Patient-important outcomes can support claims about benefit when the temporal sequence, comparator, and competing explanations are sufficiently addressed.

This article develops that distinction without assuming that treatment modification is the only mechanism through which pharmacists affect patients. Counseling, monitoring, adherence support, detection of evolving risk, and coordination can sometimes improve care while leaving the formal medication regimen unchanged. The more limited proposition is that when value is specifically attributed to pharmacist-induced treatment modification, the modification itself and its downstream consequences must be demonstrated rather than inferred from the number of activities performed.

Activity counts as measures of service production

Activity measures answer an operational question: what did the pharmacist do? Depending on the service, the numerator may include medication reviews completed, discrepancies identified, drug-related problems detected, recommendations written, recommendations communicated, medicines discussed, patients counseled, or interventions documented. These measures can be indispensable for workforce planning, implementation monitoring, service comparison, and estimating the volume of pharmacist input. Their interpretive problem arises when a measure of production is treated as a measure of downstream exposure.

A deprescribing-focused pharmacist medication-review service illustrates the distinction. In that implementation study, pharmacists generated 221 recommendations, while only about 30% were accepted [6]. The recommendation count accurately captures pharmacist work and the number of potential treatment changes identified. It cannot establish that 221 treatment modifications occurred, because most recommendations did not cross the subsequent uptake stage. The difference is scientifically consequential rather than semantic. If a service

produces more recommendations because it serves patients with greater medication complexity, its intervention count may rise even when the proportion resulting in clinically appropriate treatment modification remains unchanged. Conversely, a service with fewer recommendations may be highly selective and achieve a larger proportion of consequential changes.

The interpretation of activity counts is further complicated by the denominator. Counts may rise because more patients were seen, because cases were more complex, because pharmacists documented more completely, because the threshold for recording an intervention changed, or because the service became more integrated into clinical decision-making. Without information on eligible patients, opportunities for intervention, severity or importance of detected problems, and downstream response, two identical activity totals can represent very different services.

Acceptance rate is often introduced to strengthen the interpretation. It moves the measurement closer to clinical decision-making because it captures whether another decision-maker agreed with the recommendation. Yet acceptance is itself context-sensitive. Observational evidence from hospital clinical-pharmacy practice shows that acceptance rates can change as pharmacists become more integrated into the care environment [7]. This makes acceptance a meaningful implementation indicator, but it also shows why it should not be interpreted as an intrinsic property of recommendation quality. Acceptance may reflect trust, workflow, timing, professional role, communication mode, local authority, patient preferences, or the availability of new clinical information.

Activity and acceptance should therefore be reported as separate measures with different inferential purposes. Activity establishes that pharmacist work occurred. Acceptance establishes that a recommendation entered the clinical decision process and was endorsed at that stage. Neither measure, by itself, demonstrates that the patient was exposed to a changed medication regimen.

Recommendation uptake as a conditional implementation event

The next distinction concerns what happens after a recommendation is made. Terms such as *accepted*, *actioned*, and *implemented* are sometimes used as though they describe the same event. Empirical studies suggest that they should be separated whenever the data allow.

In a post-discharge patient-centred medicines review service, 368 recommendations were generated and 351 were subsequently actioned, yet only 284 were reported as implemented; 206 medicines were ultimately deprescribed [8]. Each number describes a different stage. Recommendation generation records pharmacist activity. Actioning indicates that the recommendation entered an active response process. Implementation indicates that an intended change was actually carried out. Deprescribing identifies one concrete form of medication modification. Treating all four as interchangeable would erase where loss occurred in the pathway.

Implementation is conditional because the recommendation encounters additional decision-makers and changing clinical circumstances. Qualitative research examining why physicians did or did not implement hospital pharmacists' medication-appropriateness recommendations identified influences related to recommendation characteristics, pharmacist–physician interaction, perceived professional roles, clinical relevance, trust, and environmental conditions [9]. These findings make the acceptance–implementation relationship mechanistic rather than merely administrative. A recommendation can be clinically reasonable and still remain unimplemented because the patient declines it, the prescriber receives new information, another clinician changes the plan, the medication is unavailable, follow-up fails, or the clinical priority changes.

The distinction is especially clear in deprescribing research conducted in residential aged care. Pharmacists generated 1,222 deprescribing recommendations, of which 941 were accepted by general practitioners. Twelve months later, 692 of the accepted recommendations had been implemented [10]. Thus, acceptance represented an important intermediate event, while verified implementation identified a smaller downstream exposure. The gap is directly relevant to causal inference. An evaluation that classified every accepted recommendation as an implemented treatment change would misclassify exposure for a substantial proportion of recommendations in that setting.

This does not mean that nonimplementation is necessarily a failure. A recommendation can appropriately be reconsidered as circumstances evolve. Nor does high implementation necessarily prove better care; an inappropriate recommendation can also be implemented. The analytical requirement is more modest: investigators should identify which event they measured and restrict the claim accordingly.

For service evaluation, uptake can therefore be represented as a conditional transition rather than a binary validation of pharmacist value. Useful measures include the proportion of recommendations communicated,

accepted, scheduled for action, implemented, modified before implementation, reversed after implementation, or still active at a prespecified follow-up. These measures become more informative when their denominators and observation periods are explicit. They also create the information needed to determine whether an observed patient outcome could plausibly have resulted from the pharmacist-initiated treatment pathway.

Actual medication modification as the pharmacotherapy-level causal hinge

When a pharmacist recommendation concerns pharmacotherapy, verified medication modification is the point at which a proposed change becomes an altered treatment exposure. The modification may involve initiation, discontinuation, dose adjustment, formulation change, scheduling change, duplication removal, interaction management, monitoring-linked dose adaptation, or another clinically meaningful alteration. For causal interpretation, the decisive feature is that treatment received by the patient differs from what would otherwise have occurred.

Randomized evaluations demonstrate why the distinction matters. In a neonatal intensive care setting, adding a clinical pharmacist altered medication-related safety processes and drug-related problem management compared with standard practice [11]. In outpatient cardiology, pharmacist-led medication review reduced the number of drug-related problems and substantially increased resolution of identified problems [12]. These studies provide stronger evidence of pharmacotherapy-level change than a recommendation count because the evaluation observes a downstream medication-related consequence. Nevertheless, the measured endpoint remains different from a patient-important outcome. Resolution of a drug-related problem may be a necessary step toward safer or more effective treatment, while the magnitude of patient benefit depends on the nature of the problem, its clinical importance, the duration of exposure, and subsequent events.

Medication modification also requires careful classification because not every recorded medication difference represents the same phenomenon. A controlled post-discharge study found that pharmacist-supported reconciliation and counseling reduced clinically important unintentional patient-generated medication discrepancies, whereas clinically important intentional discrepancies were not similarly reduced [13]. This distinction matters because a discrepancy caused by misunderstanding, communication failure, or accidental omission has a different causal meaning from a deliberate patient decision. Combining them into one medication-change outcome could obscure the mechanism through which the pharmacist intervention operated.

The concept of medication modification should therefore be operational rather than nominal. A study claiming that pharmacist activity changed treatment should specify what changed, when it changed, who authorized or enacted the change, and whether the change persisted long enough to constitute meaningful exposure. For deprescribing, confirmation that a medicine was actually discontinued is stronger evidence than recommendation acceptance. For dose adjustment, a written recommendation is weaker evidence than a documented new dose followed by evidence that the patient received it. For adherence-oriented services, the relevant treatment exposure may be changed medication-taking behavior rather than a new prescription.

This qualification prevents treatment modification from becoming an unnecessarily rigid mediator. Some pharmacist services are designed primarily to educate patients, improve adherence, detect emerging toxicity, support self-management, or coordinate care. In those services, a beneficial causal pathway can occur without altering the prescribed regimen. The pharmacotherapy-level hinge is therefore required when the claimed mechanism is pharmacist-induced medication modification, not as a universal requirement for every form of pharmaceutical care.

The central evaluative implication is that recommendation acceptance should not be used as a surrogate for changed treatment when actual implementation can be measured. Verification narrows the causal distance between pharmacist activity and the treatment exposure hypothesized to affect later outcomes. It also reveals where apparently successful services may lose effect before reaching the patient.

Intermediate medication outcomes and their evidentiary role

After treatment modification or another successfully enacted pharmacist intervention, evaluation commonly turns to medication-related intermediate outcomes. These include drug-related problems, medication discrepancies, adherence, medication burden, prescribing appropriateness, exposure to anticholinergic or sedative medicines, antimicrobial use, and related safety or process measures. They occupy an important position between implementation and patient-important benefit because they can demonstrate that the intervention altered the medication-use pathway in the expected direction.

Evidence from oncology illustrates their usefulness. A systematic review and meta-analysis of randomized trials reported favorable effects of pharmacist-led interventions on medication-related problems and adherence, with evidence of improvement in adverse-drug-event outcomes in the included analyses [14]. Such findings support the claim that pharmacist interventions can modify clinically relevant medication processes. They do not establish that every pharmaceutical-care activity producing a documented intervention yields the same consequence, because the interventions, mechanisms, patient risks, and measured outcomes differ across trials.

Even apparently similar safety outcomes require separation. A meta-analysis examining pharmacist interventions and adverse drug events found a reduction in observed adverse drug events, whereas the estimate for potentially adverse drug events was not statistically conclusive [15]. This divergence demonstrates why endpoint naming matters. An actual adverse drug event, a prevented error, a potentially preventable adverse event, and a pharmacist-detected medication problem describe different states. Collapsing them into a single category such as "clinical impact" can convert heterogeneous evidence into a stronger claim than the underlying measurements justify.

Mixed evidence from community-pharmacy antibiotic interventions provides another boundary condition. Systematic review evidence found benefits for selected antibiotic-use outcomes, while effects on adherence and patient-centered outcomes were inconsistent, and the included studies carried unclear or high risk of bias in at least one assessed domain [16]. The appropriate interpretation is neither that these interventions are ineffective nor that process changes establish patient benefit. Instead, the evidence indicates that proximal intervention effects, behavioral responses, and downstream clinical outcomes may diverge.

A randomized medication-review trial targeting anticholinergic and sedative load in older patients provides a particularly useful falsification case. The pharmacist-led intervention did not significantly improve the primary Drug Burden Index endpoint, although some secondary outcomes suggested benefit [17]. This pattern is important for causal reasoning because it prevents the conceptual sequence from becoming self-confirming. If the hypothesized proximal medication target does not change, a later patient benefit cannot automatically be attributed to that pathway; alternative mechanisms, measurement limitations, timing, or chance remain possible. Conversely, failure of one proximal endpoint does not negate all other effects of the service.

Intermediate medication outcomes therefore strengthen causal interpretation when three conditions are met. First, the outcome should correspond to the mechanism through which the pharmacist intervention is expected to work. Second, it should be measured after the relevant intervention has actually been implemented. Third, it should not be described as patient benefit unless the outcome itself constitutes experienced harm or benefit of direct importance to patients. A prevented serious adverse drug event can plainly be patient-important, whereas an improvement in a medication-appropriateness score or reduction in theoretical drug burden is usually better treated as an intermediate measure unless a validated link to subsequent patient experience is demonstrated.

This measurement discipline permits a more informative account of pharmaceutical-care value. Service activity establishes that professional work occurred; uptake establishes that the recommendation entered decision-making; verified modification establishes that treatment exposure changed; and intermediate medication outcomes show whether the expected medication-use consequence emerged. The remaining question is whether these changes produce durable benefit that matters to patients, and what evidence is required to attribute that benefit to the pharmacist intervention rather than to concurrent care, natural recovery, baseline risk, or other competing explanations.

Patient-important benefit and temporal downstream attribution

The strongest claim about pharmaceutical-care value concerns an outcome experienced by the patient rather than merely an improvement in a medication-use process. Health-related quality of life, symptoms, functional status, serious medication-related harm, hospitalization, treatment burden, and survival are examples whose importance is comparatively direct. Their position downstream of pharmacist activity makes them valuable endpoints, but also makes attribution more difficult because more events can intervene between the original pharmacist action and the observed result.

Randomized medication-review studies demonstrate this complexity. In geriatric outpatients with polypharmacy, a comprehensive medication-review intervention produced short-term improvement in health-related quality of life and reduced medication use, while several longer-term outcomes were not significantly different [18]. A goal-focused clinical medication review likewise improved self-rated health on the EQ-VAS and reduced impactful health problems, although the EQ-5D and total number of health problems did not show equivalent improvement

[19]. A separate randomized trial of a multifaceted clinical-pharmacist intervention after hospitalization failed to improve its primary medication-safety outcome [20]. Taken together, these trials show that patient-important effects can be positive, null, instrument-dependent, and time-dependent [18-20].

The implication is not that downstream outcomes are inherently more legitimate than medication-related intermediate outcomes. They answer a different question. A reduction in a well-defined drug-related problem can demonstrate that medication management changed in the intended direction. Improvement in quality of life addresses whether that change, together with any other intervention mechanisms, affected the patient's lived health. Neither result should be substituted for the other.

Temporal specification is therefore central to attribution. A treatment modification must precede an outcome that it is proposed to cause, and the observation period must be long enough for the relevant pharmacological or behavioral effect to emerge. A short follow-up may detect medication discontinuation but miss later improvement in symptoms or function. A long follow-up may capture clinically meaningful consequences while simultaneously allowing substantial contamination from new diagnoses, treatment changes, hospitalizations, clinician decisions, or patient behavior.

The evidentiary claim should consequently be expressed at the level actually observed. When only service activity is measured, the appropriate conclusion concerns service production. When implementation and medication modification are documented, a treatment-change claim becomes supportable. When a prespecified patient-important endpoint changes under a design capable of estimating an attributable effect, the evidence can support a stronger statement about pharmaceutical-care benefit.

The progression in evidentiary strength and the corresponding limits on inference are summarized below.

Table 1. Measurement levels in pharmacist-service evaluation and the clinical claims each level can support

Measurement object	What is directly observed	Essential denominator or time anchor	Inference legitimately supported	Inference not justified from this level alone	Next evidentiary step
Completed pharmacist activity	Review, consultation, reconciliation, counseling episode, documented intervention	Eligible patients, encounters, or service opportunities	Service volume, reach, workload, implementation activity	Treatment change, medication improvement, patient benefit	Determine whether an actionable recommendation or intervention resulted
Recommendation generated	Specific proposed medication or care action	All recommendations generated or all eligible problems	Pharmacist identification of a potential change	Acceptance, implementation, appropriateness of the eventual treatment, benefit	Measure response to the recommendation
Recommendation accepted	Clinician, patient, or team agreement at the decision stage	Recommendations reaching the relevant decision-maker	Uptake or agreement	Actual exposure to changed treatment	Verify enactment and timing
Recommendation actioned	Follow-up action initiated in response to the recommendation	Accepted or communicated recommendations	Progress toward implementation	Completed or persistent medication modification	Confirm what was actually changed
Verified medication modification	Initiation, discontinuation, dose/formulation/schedule change or other documented alteration in treatment received	Recommendations eligible to produce treatment change; prespecified follow-up	Pharmacotherapy exposure changed	Improvement in medication outcome or patient health	Measure pathway-consistent intermediate outcome
Intermediate medication outcome	Change in adherence, discrepancy, drug-related problem, medication burden, prescribing appropriateness or related medication state	Baseline state and prespecified post-intervention assessment	Medication-use pathway changed	Broader patient benefit unless the endpoint itself constitutes clinically experienced benefit or harm	Measure appropriate patient-important endpoint

Patient-important outcome	Change in symptoms, function, quality of life, serious harm, hospitalization or other directly consequential endpoint	Valid comparator and clinically appropriate follow-up	Patient outcome differs between evaluated conditions	Causal attribution to pharmacist activity without an adequate counterfactual and control of competing explanations	Estimate attributable effect using an appropriate causal design

Confounding, selection, co-intervention, and documentation threats

Even a fully observed sequence from pharmacist activity to treatment modification and outcome does not automatically establish causation. The same clinical features that generate pharmacist involvement may also predict the outcome. Patients with polypharmacy, severe illness, renal dysfunction, multiple prescribers, recent hospitalization, or prior medication problems are more likely to attract pharmacist attention and more likely to experience adverse outcomes. A crude comparison of patients with and without pharmacist interventions can therefore make an effective service appear harmful through confounding by indication.

Selection can occur earlier still. Patients referred to medication-review services may differ from those not referred in engagement, clinical complexity, clinician concern, access to care, or likelihood of follow-up. Among those receiving recommendations, implementation is additionally shaped by professional trust, perceived relevance, patient preference, and service environment. These implementation processes cannot be assumed to distribute randomly.

Fidelity introduces another layer. Complex interventions can be delivered and received without being fully enacted. Process evaluation of a team-based healthcare intervention has demonstrated that delivery, receipt, and enactment can diverge and that enactment may relate more closely to outcomes than nominal exposure to the intervention [21]. Applied cautiously to pharmaceutical care, this implies that documenting delivery of a pharmacist service does not guarantee that the mechanism expected to produce benefit actually operated.

Mediation analysis can help distinguish a total service effect from effects transmitted through treatment modification or other intermediates, but it requires explicit definition of exposure, mediator, outcome, temporal order, and confounding assumptions. The AGReMA reporting guidance underscores that mediation claims demand considerably more information than simply showing that an intervention and an outcome are statistically associated [22].

The principal causal threats specific to pharmacist-service evaluation are summarized below.

Table 2. Causal threats that can create misleading estimates of pharmacist-service value

Causal threat	Where it enters the service-to-outcome sequence	How a misleading value signal can arise	Observable diagnostic clue	Design or analytical response	Residual limitation
Confounding by indication	Before pharmacist involvement	Higher-risk patients receive more pharmacist input and also have worse outcomes	Intervention frequency rises with baseline severity or medication complexity	Randomization, restriction, matching, weighting, adjustment, target-trial specification	Unmeasured severity may remain
Selection into the service	Referral or eligibility stage	Referred patients differ systematically from nonparticipants	Different baseline engagement, morbidity, access, prescriber concern	Explicit eligibility criteria; compare eligible treated and untreated populations	Referral motives may be incompletely recorded
Uptake-related selection	Recommendation acceptance or implementation	Easier, safer, or more acceptable recommendations are preferentially implemented	Implemented recommendations differ in type or complexity from rejected ones	Analyze recommendation-level determinants; separate intention-to-intervene from implementation effects	Post-recommendation variables can themselves be causal intermediates

Co-intervention	After pharmacist contact	Concurrent clinician, nurse, caregiver, digital or organizational actions produce the observed outcome	Multiple care changes occur during the same interval	Protocolize co-interventions where possible; document and model concurrent care	Complex care pathways may resist complete separation
Regression to the mean	Triggering abnormal value or acute event	Outcomes improve after unusually poor baseline measurements even without intervention	Service initiated at an extreme laboratory, adherence, symptom or utilization value	Appropriate control group; repeated baseline measurements	Natural-history variation may remain
Secular or organizational change	During service rollout	Outcome improves because the wider system changes	Similar trend occurs in nonexposed services or before full implementation	Difference-in-differences or interrupted time series with adequate controls	Concurrent policies can violate assumptions
Documentation bias	Activity, implementation, or outcome recording	Better-integrated pharmacists create more complete records, inflating apparent intervention or resolution rates	Documentation intensity changes without corresponding clinical exposure	Standardized definitions; independent outcome ascertainment; audit of missingness	Undocumented actions remain difficult to recover
Misaligned time zero	Start of follow-up	Patients must survive or remain under observation long enough to be classified as implemented	Follow-up begins before treatment strategy is consistently defined	Align eligibility, exposure assignment and follow-up initiation	Routine data may not contain precise implementation times

Evaluation designs that can identify the causal sequence

Randomization remains the clearest method for estimating a total effect when assignment to pharmacist involvement can ethically and practically be randomized. Many real-world services, however, are introduced through routine referral, phased implementation, hospital policy, or system redesign. In these circumstances, stronger observational designs are required if the conclusion is intended to be causal rather than descriptive.

Target-trial emulation provides a useful discipline because it requires investigators to specify the hypothetical trial their observational analysis is intended to approximate, including eligibility, treatment strategies, assignment, time zero, follow-up, outcome, causal contrast, and analysis [23]. Applying trial principles before analyzing routine data can reduce ambiguities that otherwise allow exposure classification or follow-up to depend on future information [24]. For pharmacist services, the relevant "treatment strategy" might be assignment to a defined pharmacist-led review pathway rather than the post hoc presence of any documented pharmacist intervention.

When implementation occurs at a service or policy level, difference-in-differences can estimate whether outcome changes exceeded those occurring in a comparison group, provided the identifying assumptions are credible [25]. Interrupted time-series designs can similarly estimate changes in outcome level or trajectory after implementation, although methodological reviews show that such studies are frequently weakened by inadequate modelling of pre-existing trends, autocorrelation, seasonality, or other biases [26]. Applied health-service research also demonstrates that policy implementation can coexist with little or no attributable change in targeted service outcomes, illustrating why intervention introduction or activity volume cannot substitute for causal estimation [27].

These designs address the counterfactual question: what would probably have happened to comparable patients or services without the evaluated pharmacist intervention? Measurement of the causal sequence addresses a complementary question: through what observed pathway did the effect occur? Strong evaluation can use both.

Figure 1 maps the relationships among pharmacist activity, implementation, treatment exposure, and patient benefit, together with competing influences on attribution.



Figure 1. Attribution structure linking pharmacist activity to patient benefit

Testable propositions and boundary conditions

The synthesis yields several falsifiable propositions. First, services with greater documented pharmacist activity should not necessarily show proportionately greater verified treatment modification after differences in case mix and opportunity are considered. Second, acceptance rates should systematically overestimate treatment exposure in settings where accepted recommendations are incompletely enacted. Third, treatment modification can improve an intermediate medication outcome without producing detectable improvement in a patient-important outcome within the same observation period. Fourth, apparent patient benefit occurring without pathway-consistent implementation should increase the plausibility of alternative mechanisms, including counseling, adherence support, concurrent care, selection, or natural clinical change.

These propositions have boundaries. Autonomous pharmacist prescribing can collapse the distinction between recommendation and prescriber acceptance. Some services operate primarily through education, monitoring, or coordination and may legitimately benefit patients without modifying a prescription. A serious adverse drug event is simultaneously a medication-related endpoint and a directly patient-important event. Finally, a well-designed randomized trial can estimate the total effect of a pharmacist service without measuring every mediator, although claims about *how* the effect occurred still require pathway evidence.

Results and Discussion

Pharmaceutical-care evaluation becomes more interpretable when reporting distinguishes what was done, what was accepted, what was implemented, what treatment actually changed, what medication-related consequence followed, and what happened to the patient. These quantities answer different questions and should not be combined into a single intervention-impact metric.

For researchers, the practical implication is to design data collection around the causal claim intended at the end of the study. A workload or implementation study may appropriately stop at activity and uptake. A study attributing medication optimization to a treatment change should verify that modification. A study claiming patient benefit should measure a patient-important endpoint and use a design capable of distinguishing the intervention effect from credible alternatives.

For healthcare organizations and commissioners, activity counts remain valuable for operational accountability. Their limitation is interpretive, not administrative. Counting reviews, interventions, or accepted recommendations can show whether a service is functioning and reaching patients. It cannot determine the amount of health benefit produced unless downstream exposure and outcomes are linked to those activities.

The same reasoning discourages another common simplification: treating a high acceptance rate as a universal quality indicator. Appropriate rejection can reflect careful clinical judgment, while inappropriate acceptance can still occur. Quality therefore depends on the clinical validity of recommendations, their enactment when appropriate, and the consequences of the resulting care.

The principal limitation of this conceptual synthesis is that no single evidence base measures every link in the proposed sequence under one common design. The literature combines medication-review trials, implementation studies, recommendation-uptake analyses, patient-outcome trials, fidelity research, and general causal-inference methods. The contribution is consequently methodological and interpretive rather than a new estimate of pharmacist effectiveness. Future evaluations can test the propositions directly by recording recommendation-level progression, time-stamped medication modification, intermediate outcomes, patient outcomes, and the counterfactual structure required for causal estimation.

Conclusion

Pharmacist intervention counts are legitimate measures of professional activity, but their clinical meaning depends on what happens after the activity is recorded. A recommendation can be rejected, accepted but not implemented, implemented without producing the intended medication effect, or followed by a medication improvement that does not translate into patient benefit. The opposite is also possible: pharmacists can improve patient care through mechanisms that do not require medication modification.

Claims about pharmaceutical-care value should therefore be calibrated to the most downstream event that has actually been observed and credibly attributed. Service activity supports statements about work performed; uptake supports statements about decision-process engagement; verified medication modification supports statements about changed treatment; intermediate outcomes support pathway-specific clinical interpretation; and patient-important outcomes support claims of benefit only when an adequate counterfactual and competing explanations are addressed. The central issue is not whether pharmacist interventions are valuable, but whether the evidence collected is capable of identifying the particular value being claimed.

Acknowledgments: None

Conflict of Interest: None

Financial Support: None

Ethics Statement: None

References

1. Craske ME, Hardeman W, Steel N, Twigg MJ. Components of pharmacist-led medication reviews and their relationship to outcomes: A systematic review and narrative synthesis. BMJ Qual Saf. 2024;33(12):808-22. doi:10.1136/bmjqs-2024-017283
2. Vogt CJ, Moecker R, Jacke CO, Haefeli WE, Seidling HM. Exploring the heterogeneity in community pharmacist-led medication review studies—a systematic review. Res Social Adm Pharm. 2024;20(8):679-88. doi:10.1016/j.sapharm.2024.03.012
3. Al-Babtain B, Cheema E, Hadi MA. Impact of community-pharmacist-led medication review programmes on patient outcomes: A systematic review and meta-analysis of randomised controlled trials. Res Social Adm Pharm. 2022;18(4):2559-68. doi:10.1016/j.sapharm.2021.04.022
4. Rattanavipanon W, Chaiyasothi T, Puchsaka P, Mungkornkaew R, Nathisuwan S, Veettil SK, et al. Effects of pharmacist interventions on cardiovascular risk factors and outcomes: An umbrella review of meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022;88(7):3064-77. doi:10.1111/bcp.15279
5. Ali S, Salahudeen MS, Bereznicki LRE, Curtain CM. Pharmacist-led interventions to reduce adverse drug events in older people living in residential aged care facilities: A systematic review. Br J Clin Pharmacol. 2021;87(10):3672-89. doi:10.1111/bcp.14824
6. Alaa Eddine N, Schreiber J, El-Yazbi AF, Shmaytilli H, Amin MEK. A pharmacist-led medication review service with a deprescribing focus guided by implementation science. Front Pharmacol. 2023;14:1097238. doi:10.3389/fphar.2023.1097238
7. Peled O, Vitzrabin Y, Beit Ner E, Lazaryan M, Berlin M, Barchel D, et al. Acceptance rate of clinical pharmacists' recommendations—an ongoing journey for integration. Front Pharmacol. 2023;14:1253990. doi:10.3389/fphar.2023.1253990

8. Basger BJ, Moles RJ, Chen TF. Uptake of pharmacist recommendations by patients after discharge: Implementation study of a patient-centered medicines review service. BMC Geriatr. 2023;23(1):183. doi:10.1186/s12877-023-03921-2
9. Dalton K, Fleming A, O'Mahony D, Byrne S. Factors affecting physician implementation of hospital pharmacists' medication appropriateness recommendations in older adults. Br J Clin Pharmacol. 2022;88(2):628-54. doi:10.1111/bcp.14987
10. Quek HW, Etherton-Beer C, Page A, McLachlan AJ, Lo SY, Naganathan V, et al. Deprescribing for older people living in residential aged care facilities: Pharmacist recommendations, doctor acceptance and implementation. Arch Gerontol Geriatr. 2023;107:104910. doi:10.1016/j.archger.2022.104910
11. Yalçın N, Kaşıkcı M, Çelik HT, Allegaert K, Demirkan K, Yiğit Ş. Impact of clinical pharmacist-led intervention for drug-related problems in neonatal intensive care unit: A randomized controlled trial. Front Pharmacol. 2023;14:1242779. doi:10.3389/fphar.2023.1242779
12. Huiskes VJB, van den Ende CHM, Kruijtbosch M, Ensing HT, Meijs M, Meijs VMM, et al. Effectiveness of medication review on the number of drug-related problems in patients visiting the outpatient cardiology clinic: A randomized controlled trial. Br J Clin Pharmacol. 2020;86(1):50-61. doi:10.1111/bcp.14125
13. Jošt M, Knez L, Kos M, Kerec Kos M. Pharmacist-led hospital intervention reduces unintentional patient-generated medication discrepancies after hospital discharge. Front Pharmacol. 2024;15:1483932. doi:10.3389/fphar.2024.1483932
14. Fentie AM, Huluka SA, Gebremariam GT, Gebretekle GB, Abebe E, Fenta TG. Impact of pharmacist-led interventions on medication-related problems among patients treated for cancer: A systematic review and meta-analysis of randomized control trials. Res Social Adm Pharm. 2024;20(5):487-97. doi:10.1016/j.sapharm.2024.02.006
15. Kelly WN, Ho MJ, Smith T, Bullers K, Bates DW, Kumar A. Association of pharmacist interventions with adverse drug events and potential adverse drug events. Pharmacoepidemiol Drug Saf. 2024;33(7):e5853. doi:10.1002/pds.5853
16. Lambert M, Smit CCH, De Vos S, Benko R, Llor C, Paget WJ, et al. A systematic literature review and meta-analysis of community pharmacist-led interventions to optimise the use of antibiotics. Br J Clin Pharmacol. 2022;88(6):2617-41. doi:10.1111/bcp.15254
17. van der Meer HG, Wouters H, Pont LG, Taxis K. Reducing the anticholinergic and sedative load in older patients on polypharmacy by pharmacist-led medication review: A randomised controlled trial. BMJ Open. 2018;8(7):e019042. doi:10.1136/bmjopen-2017-019042
18. Kornholt J, Feizi ST, Hansen AS, Laursen JT, Reuther LØ, Petersen TS, et al. Effects of a comprehensive medication review intervention on health-related quality of life and other clinical outcomes in geriatric outpatients with polypharmacy: A pragmatic randomized clinical trial. Br J Clin Pharmacol. 2022;88(7):3360-9. doi:10.1111/bcp.15287
19. Verdoorn S, Kwint HF, Blom JW, Gussekloo J, Bouvy ML. Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: A randomised controlled trial (DREAMeR-study). PLoS Med. 2019;16(5):e1002798. doi:10.1371/journal.pmed.1002798
20. Gurwitz JH, Kapoor A, Garber L, Mazor KM, Wagner J, Cutrona SL, et al. Effect of a multifaceted clinical pharmacist intervention on medication safety after hospitalization in persons prescribed high-risk medications: A randomized clinical trial. JAMA Intern Med. 2021;181(5):610-8. doi:10.1001/jamainternmed.2020.9285
21. Ginsburg LR, Hoben M, Easterbrook A, Andersen E, Anderson RA, Cranley L, et al. Examining fidelity in the INFORM trial: A complex team-based behavioral intervention. Implement Sci. 2020;15(1):78. doi:10.1186/s13012-020-01039-2
22. Lee H, Cashin AG, Lamb SE, Hopewell S, Vansteelandt S, VanderWeele TJ, et al. A guideline for reporting mediation analyses of randomized trials and observational studies: The AGReMA statement. JAMA. 2021;326(11):1045-56. doi:10.1001/jama.2021.14075
23. Hernán MA, Wang W, Leaf DE. Target trial emulation: A framework for causal inference from observational data. JAMA. 2022;328(24):2446-7. doi:10.1001/jama.2022.21383
24. Matthews AA, Danaei G, Islam N, Kurth T. Target trial emulation: Applying principles of randomised trials to observational studies. BMJ. 2022;378:e071108. doi:10.1136/bmj-2022-071108
25. Graves JA, Fry C, McWilliams JM, Hatfield LA. Difference-in-differences for categorical outcomes. Health Serv Res. 2022;57(3):681-92. doi:10.1111/1475-6773.13948

26. Hategeka C, Ruton H, Karamouzian M, Lynd LD, Law MR. Use of interrupted time series methods in the evaluation of health system quality improvement interventions: A methodological systematic review. BMJ Glob Health. 2020;5(10):e003567. doi:10.1136/bmjgh-2020-003567
27. Anderson M, Molloy A, Maynou L, Kyriopoulos I, McGuire A, Mossialos E. Evaluation of the NHS England evidence-based interventions programme: A difference-in-difference analysis. BMJ Qual Saf. 2023;32(2):90-9. doi:10.1136/bmjqs-2021-014478